



FOR IMMEDIATE RELEASE

February 9, 2010 -- Verrow Pharmaceuticals, Inc., Receives Patent for Kidney Protective Technology

LENEXA, KS -- Verrow Pharmaceuticals, Inc., has been issued its first patent for its kidney protective technology-US patent # 7,658,913 entitled "**Compositions Useful For Reducing Nephrotoxicity And Methods Of Use Thereof**". This first issuance in our patent estate validates our technology for protecting the kidneys from the harmful effects of X-Ray dye. Several additional patents are pending in the US and internationally.

"This first patent issuance is a key step in establishing the validity of our technology." said Verrow founder and CEO Vernon Rowe, M.D. "Bringing our kidney safe X-ray dye to market will potentially prevent kidney damage and failure for millions of patients undergoing cardiology and other procedures requiring the use of X-Ray dye."

The company's lead product, Veropaque, is a kidney safe X-ray dye for use in diagnostic and interventional cardiology procedures. Cardiology patients are often at high risk for kidney damage due to obesity, diabetes, and advanced age. Kidney damage from X-ray dyes is responsible for a 3 to 5 times increase in mortality rates.

According to Geoffrey O. Hartzler, M.D., an interventional cardiologist and member of Verrow's board, "I see this as a major development for the X-ray dye we use for almost everything we do in cardiology. And we're likely to be wedded to X-ray technology for the next fifty years."

Veropaque is nearing completion of its preclinical program, and has been the subject of a PreIND meeting with the FDA. IND submission is expected in the near future. Because Veropaque is a reformulation of existing approved components, it will be developed through the FDA under an abbreviated 505(b)(2) pathway.

Consulting on this program is Dr. Peter McCullough, an internationally recognized authority on acute kidney injury and its impact on cardiology outcomes. Dr. McCullough said, "A kidney-safe contrast agent for cardiology procedures is the dream of every interventional cardiologist. We have to live with the knowledge that we may be creating a lifetime kidney problem for each patient, even as we are saving his or her life with a heart procedure. Veropaque has the potential to solve that problem."

ABOUT VERROW

Verrow Pharmaceuticals, Inc. (www.Verrow.com), a drug development company founded in 2006, is building a portfolio of lead products based on proven drugs by reformulation to make them less toxic, utilizing a proprietary platform technology.

Two pipeline products have already been discussed with the FDA in preIND meetings: Vertexate, a novel treatment for secondary progressive multiple sclerosis (SPMS); and Verplatin, a safer formulation of a platinum-containing anti-cancer agent.